Abstract
Twenty patients with mild or moderate essential hypertension participated in a double-blind crossover randomized trial aimed at assessing, by echocardiography, the hemodynamic effects of the antihypertensive therapy with atenolol administered once daily (100 mg) alone or combined with chlortalidone (25 mg) in fixed combination. Blood pressure and heart rate were measured at rest and during bicycle exercise before and after four-week periods of treatment. Both atenolol and atenolol plus chlortalidone reduced significantly blood pressure and heart rate. The reduction in blood pressure was mediated by a reduction in cardiac output. However, the combined treatment was also able to prevent the increase in stroke volume observed after atenolol alone. Furthermore, the combined treatment was able to significantly lower blood pressure during exercise, while atenolol alone failed. These results suggest that the association of chlortalidone potentiates the antihypertensive effect of atenolol by acting through a different mechanism.
| Original language | English |
|---|---|
| Pages (from-to) | 901-911 |
| Number of pages | 11 |
| Journal | Current Therapeutic Research |
| Volume | 37 |
| Issue number | 5 |
| Publication status | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Hemodynamic effects of the antihypertensive treatment with atenolol plus chlortalidone in fixed combination : A double-blind crossover comparison with atenolol. / Ricciardelli, B.; Cuocolo, A.; De Luca, N.
In: Current Therapeutic Research, Vol. 37, No. 5, 1985, p. 901-911.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hemodynamic effects of the antihypertensive treatment with atenolol plus chlortalidone in fixed combination
T2 - A double-blind crossover comparison with atenolol
AU - Ricciardelli, B.
AU - Cuocolo, A.
AU - De Luca, N.
PY - 1985
Y1 - 1985
N2 - Twenty patients with mild or moderate essential hypertension participated in a double-blind crossover randomized trial aimed at assessing, by echocardiography, the hemodynamic effects of the antihypertensive therapy with atenolol administered once daily (100 mg) alone or combined with chlortalidone (25 mg) in fixed combination. Blood pressure and heart rate were measured at rest and during bicycle exercise before and after four-week periods of treatment. Both atenolol and atenolol plus chlortalidone reduced significantly blood pressure and heart rate. The reduction in blood pressure was mediated by a reduction in cardiac output. However, the combined treatment was also able to prevent the increase in stroke volume observed after atenolol alone. Furthermore, the combined treatment was able to significantly lower blood pressure during exercise, while atenolol alone failed. These results suggest that the association of chlortalidone potentiates the antihypertensive effect of atenolol by acting through a different mechanism.
AB - Twenty patients with mild or moderate essential hypertension participated in a double-blind crossover randomized trial aimed at assessing, by echocardiography, the hemodynamic effects of the antihypertensive therapy with atenolol administered once daily (100 mg) alone or combined with chlortalidone (25 mg) in fixed combination. Blood pressure and heart rate were measured at rest and during bicycle exercise before and after four-week periods of treatment. Both atenolol and atenolol plus chlortalidone reduced significantly blood pressure and heart rate. The reduction in blood pressure was mediated by a reduction in cardiac output. However, the combined treatment was also able to prevent the increase in stroke volume observed after atenolol alone. Furthermore, the combined treatment was able to significantly lower blood pressure during exercise, while atenolol alone failed. These results suggest that the association of chlortalidone potentiates the antihypertensive effect of atenolol by acting through a different mechanism.
UR - http://www.scopus.com/inward/record.url?scp=0021857473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021857473&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0021857473
VL - 37
SP - 901
EP - 911
JO - Current Therapeutic Research - Clinical and Experimental
JF - Current Therapeutic Research - Clinical and Experimental
SN - 0011-393X
IS - 5
ER -